CHAMP clinical trial examines efficacy of NVK002 in controlling pediatric myopia
Focus of trial is to determine medication's safety, efficacy for treating myopia progression By Lynda Charters; Reviewed by Rupa K. Wong, MD, PAAR Findings from the CHAMP phase 3 study (NCT03350620) show that NVK002 atropine 0.01% (Vyluma, Inc) "meaningfully slowed" myopia progression...
Saved in:
Published in | Ophthalmology Times Vol. 49; no. 7; p. 13 |
---|---|
Main Author | |
Format | Trade Publication Article |
Language | English |
Published |
Monmouth Junction
MultiMedia Healthcare Inc
01.07.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!